Modulation of lymphocyte trafficking and drug transport with lipid prodrugs

Lymphatic Targeting Technology

Our lipid prodrug approach harnesses the body's natural lipid transport mechanisms to substantially enhance the transport of oral small molecules directly into the lymphatic system. This pathway facilitates entry into the mesenteric lymph nodes, the critical site for immune cell priming and proliferation in the GI tract.

As about 80 percent of immune cells reside in the GI tract-associated lymphatic tissues, targeting of immunomodulatory agents with this approach can tune both system and local immune status. In pursuit of this objective, we have successfully extended the platform to new drugs and linker chemistries, which continue to demonstrate promising lymphatic targeting in preclinical studies. 


  • Patient Need & Market Potential

    Disorders of the immune system create an enormous burden on patients, with diseases such as rheumatoid arthritis (20M estimated worldwide prevalence), psoriasis (50M), lupus (1.5M), multiple sclerosis (1.5M), solid organ transplants (50K), and inflammatory bowel disease (5M) challenging the health of patients

  • Our Approach to Solving the Problem
    • By addressing the immune system at the sites of dysregulation and immune control, this novel approach has the potential to radically transform the treatment of serious disease
    • Targeting the lymphatic pathway potentially enables rational design of therapeutics to modulate the immune system, representing an innovative approach to treating a broad range of serious immunological disorders, such as cancer and autoimmune diseases
    • Harnessing the biology of the lymphatic system and the endogenous trafficking of compounds through the lymphatic network enables the development of novel drugs that bypass first-pass metabolism, improve oral bioavailability, and significantly lower the risk of liver toxicity
  • Collaborations
    • We entered into an exclusive licensing agreement with Monash University based on the pioneering research of Dr. Christopher Porter

As about 80 percent of immune cells reside in the GI tract-associated lymphatic tissues, targeting of immunomodulatory agents with this approach can tune both system and local immune status. In pursuit of this objective, we have successfully extended the platform to new drugs and linker chemistries, which continue to demonstrate promising lymphatic targeting in preclinical studies.